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Increased interferon gamma production by peripheral blood
mononuclear cells in response to stimulation of overexpressed
disease-specific 9-O-acetylated sialoglycoconjugates in children
suffering from acute lymphoblastic leukaemia
Sialic acids, commonly referred to as N-acetyl neuraminic acid
(Neu5Ac) are a family of 9-carbon carboxylated monosaccha-
rides. Amongst 50 known derivatives of sialic acids, 7, 8 and 9-
O-acetylated derivatives (O-AcSA) are important constituents
of the cell membrane and known to influence many physio-
logical and pathological processes (Schauer, 2000, 2004)
including cell–cell adhesion, signalling, differentiation, and
metastasis (Shi et al, 1996; Kelm & Schauer, 1997; Corfield
et al, 1999; Kohla et al, 2002).
Childhood acute lymphoblastic leukaemia (ALL) may be
defined as a clonal lymphoproliferative disorder characterized
by marked overproduction of lymphoblasts and represents
the commonest type of paediatric cancer (Hoelzer et al,
2002). Although current treatment cures almost 80% of cases,
the risk of relapse remains in 20% of patients in remission
that harbour residual leukaemic blasts. Therefore, an urgent
need exists to study the disease-biology in ALL. In this
regard, we have previously reported an over-expression of
disease-specific 9-O-acetylated sialoglycoconjugates (9-O-AcS-
Gs) on peripheral blood mononuclear cells (PBMC) of
childhood ALL patients (PBMCALL; Sinha et al, 1999a;
Mandal et al, 2000; Pal et al, 2004a,b), exploiting the selective
binding affinity of a lectin, Achatinin-H, towards 9-O-
AcSAa2-6GalNAc (Mandal & Basu, 1987; Sen & Mandal,
1995). The importance of these 9-O-AcSGs was further
shown by demonstrating the gradual decline of 9-O-AcSGs
with treatment, and their reappearance with frank relapse
(Sinha et al, 1999b–d; Pal et al, 2004a,b). Additionally,
lymphoproliferation of PBMCALL, at very low dose of
Achatinin-H, has been documented, which was further
exploited to develop a non-invasive assay for evaluating the
clinical status of these children (Sinha et al, 1999b–d). These
observations led us to explore the role of disease-specific 9-O-
AcSGs in regulating signalling for lymphoproliferation of
PBMCALL and therefore, this study aims to understand their
biological functioning.
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Summary
Disease-specific over-expression of 9-O-acetylated sialoglycoconjugates (9-O-
AcSGs) on peripheral blood mononuclear cells (PBMC) of children with
acute lymphoblastic leukaemia (ALL, PBMCALL) has been demonstrated
using a lectin, Achatinin-H, with specificity towards 9-O-AcSAa2-6GalNAc.
This study investigated the contributory role of 9-O-AcSGs induced on
PBMCALL. Stimulation of PBMCALL with Achatinin-H through 9-O-AcSGs
led to a lymphoproliferative response with a significantly increased
interferon-c (IFN-c) production when compared with unstimulated cells as
demonstrated by enzyme-linked immunosorbent assay and mRNA
expression. Under identical conditions, PBMCALL ablated of O-acetylations
did not respond to such stimulation. In summary, it may be concluded that
stimulation of over-expressed 9-O-AcSGs regulate signalling for proliferation,
leading to the release of IFN-c. Controlled expression of these molecules may
be exploited as potential targets for therapy, promising beneficial effects to
children with ALL.
Keywords: childhood acute lymphoblastic leukaemia, Achatinin-H, O-acety-
lated sialic acid binding lectin, 9-O-acetylated sialoglycoconjugates, inter-
feron gamma.
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Accordingly, the present investigation focused on the (i)
expression of 9-O-AcSGs having terminal 9-O-AcSAa2-6Gal-
NAc glycotopes on different subsets of PBMCALL, (ii) stimu-
lation of these 9-O-AcSGs and (iii) released cytokine profiles in
response to this stimulation.
Materials and methods
Reagents
Monoclonal antibodies both for cytokine assay and flow
cytometric studies were obtained from B.D. Pharmingen (San
Diego, CA, USA). The primers were from Gibco-BRL. All
other reagents and chemicals were obtained from Life Tech-
nologies (Grand Island, NY, USA).
Probes: Achatinin-H
The lectin, Achatinin-H was purified from haemolymph of the
African giant land snail Achatina fulica by affinity chromatog-
raphy using bovine submaxillary mucin (BSM) as the affinity
matrix, because of its high content (22.5%) of 7(8)9-O-AcSA
(Chatterjee et al, 1998; Sharma et al, 1998). Purified Achati-
nin-H was filter sterilized, stored at 4C and found to be stable
for 2 years. The preferential affinity of Achatinin-H towards 9-
O-AcSAa2-6GalNAc was established (Mandal & Basu, 1987;
Sen & Mandal, 1995). The lectin, either un-conjugated or
conjugated with flourescein isothiocyanate (FITC), was used as
an analytical probe for all experiments.
Study population
The study subjects (n ¼ 30) included clinically and immuno-
phenotypically confirmed childhood ALL patients at presen-
tation comprising of 20 males and 10 females, M:F in the ratio
of 2:1, with a median age of 2Æ25 years (range 0Æ8–14 years)
and a median white blood cell (WBC) count of 7Æ75 · 109/l
(range 3Æ5–11 · 109/l). Cytological examination of both per-
ipheral and bone marrow samples were routinely diagnosed
according to the French–American–British Group recommen-
dations (Burns et al, 1981) and were immunophenotyped
using commercially available anti-CD monoclonal antibodies.
Briefly, PBMC were gated for lymphocytes by staining with
anti-CD45 monoclonal antibody. Within the cases diagnosed,
immunologic subgroups were defined as follows: common
B- (n ¼ 19, CD19+, CD20+, CD10±, cyt-l+), and T- (n ¼ 11,
CD2±, CD3+, and CD7+) ALL. The diagnosis was further
validated by fluorescence-activated cell sorting (FACS) analysis
using two in-house probes, Achatinin-H and anti-9-O-AcSG
antibody, specific towards 9-O-AcSAa2-6GalNAc glycotope.
All the diagnosed patients had 80–90% lymphoblasts detected
both by morphological and immunophenotyping studies,
irrespective of the lineages. Simultaneously, diagnosis was
confirmed by detecting anti-9-O-AcSG antibody in the sera of
ALL patients (Pal et al, 2000, 2001). Age-matched, normal
healthy individuals (n ¼ 20) of either sex with different blood
groups and patients with other cross-reactive haematological
diseases e.g. acute myeloid leukaemia (AML, n ¼ 10) and
chronic lymphocytic leukaemia (CLL, n ¼ 9) were included in
the study.
Venous blood (3–4 ml) collected at the Vivekananda Insti-
tute of Medical Sciences, (Kolkata, India) was sent to the Indian
Institute of Chemical Biology. Informed consent was obtained
from donors, patients, parents or guardians. The Institutional
Human Ethical Clearance Committee, as per the protocol of
Indian Council of Medical Research, approved the study.
Detection of 9-O-AcSG expression on PBMCALL subsets by
double colour FACS analysis
Double colour flow cytometric studies were performed to
detect the expression of 9-O-AcSGs on PBMCALL (B and T
lineages) and normal PBMC (PBMCN). In brief, PBMC were
separated by Ficoll gradient, washed and incubated with
phycoerythrin (PE)-conjugated anti-CD-7 (T-ALL), anti-CD-
19 (B-ALL) and FITC-Achatinin-H (0Æ1 lg) for 1 h on ice, in
the dark, then washed and fixed with paraformaldehyde (1%)
and analysed using cell quest software. Similarly, PBMC from
clinically-confirmed AML and CLL patients and normal
individuals were analysed. Viability of cells was found to be
>98%.
The expressions of 9-O-AcSGs on PBMCALL subsets were
detected by the whole blood lysis method. Briefly, whole blood
(50 ll) was incubated with FITC-Achatinin-H and PE-conju-
gated anti-CD-19, CD-10, CD-7, CD-13 and CD-14 antibodies
separately. The erythrocytes were lysed using FACS lysing
solution (BD, 2 ml in 1:10 dilution), centrifuged, washed, fixed
and analysed. Isotype-matched antibody and FITC-bovine
serum albumin (BSA) or FITC-Achatinin-H, in the presence of
unconjugated lectin control (preincubation of cells with
Achatinin-H followed by incubation with FITC-Achatinin-
H), was used as different sets of controls. Alternatively, cells
were incubated with Achatinin-H followed by anti-Achatinin-
H antibody and the bound complex was detected by FITC-
conjugated second antibody. The percentage of positive cells
was recorded, based on the threshold or background fluores-
cence provided by all these sets of controls, which gave similar
level of background fluorescence.
The specificity of Achatinin-H interaction with 9-O-
acetylations detected by esterase treatment of cells
The O-acetylation from PBMCALL, were removed by 9-O-
acetyl haemagglutinin esterase of recombinant influenza C
virus fusion protein, which specifically hydrolyses the O-acetyl
groups of sialic acid (Vlasak et al, 1987; Chatterjee et al, 2003).
Accordingly, PBMC (1 · 106) were incubated with recombin-
ant fusion protein (100 ll, 12Æ0 mU) for 1 h at 37C and
complete removal of O-acetylation was confirmed by flow
cytometry using FITC Achatinin-H as probe.
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In vitro lymphoproliferation assay
PBMCALL were cultured (1 · 105 cells/ml) separately in the
presence of Achatinin-H (0–12 lg), maintained in RPMI-1640
medium supplemented with 5% heat inactivated fetal calf
serum (FCS), 0Æ2 mg/ml penicillin/streptomycin, 0Æ1% (w/v)
l-glutamine (Medium A) at 37C in an atmosphere of 5%
CO2, in a 96-well microtitre plate for 0–48 h in triplicates. In
parallel, PBMC isolated from AML and CLL patients and
normal individuals were cultured similarly. Cell free culture
supernatants were stored at )70C for the detection of
cytokines.
The specificity of the stimulatory effect of Achatinin-H
through 9-O-AcSGs on PBMCALL was established by preincu-
bating Achatinin-H (0Æ1 lg) with the optimal inhibitory
concentration of BSM (0Æ05 lmol/l) for 1 h at 37C and
cultured for 48 h. Alternatively, esterase-treated cells cultured
in presence of Achatinin-H, cells incubated with only BSM or
esterase-treated cells alone served as the different controls.
Quantification of cell proliferation
In order to quantify the lymphoproliferation as a consequence
of Achatinin-H stimulation, viable cells were assessed both by
conventional trypan blue dye exclusion and methylthiazoltetr-
azolium (MTT) assay. MTT was prepared in phosphate-
buffered saline (PBS), filtered through 0Æ22 lm mesh
immediately before use, and diluted in RPMI-1640 medium
to 2 mg/ml (Sinha et al, 1999b). Cells were incubated with
MTT solution (100 lg) for 3 h at 37C; the formazan crystals
formed were dissolved in dimethyl sulphoxide (DMSO). The
absorbance at 570nm was a quantitative measure of cell viability.
Quantitative analysis of secreted cytokines by enzyme-
linked immunosorbent assay (ELISA)
The concentration of cytokines released into the culture
supernatants from Achatinin-H stimulated PBMCALL was
assayed by sandwich ELISA. Briefly, microtitre plates were
coated separately with anti-human interleukin (IL)-10, IL-2,
IL-12, and interferon-c (IFN-c), in 0Æ03 mol/l carbonate buffer,
pH 9Æ6 for overnight at 4C, washed and blocked with 1% BSA
for 2 h at 37C and incubated with culture supernatants
overnight. Preincubated biotinylated secondary antibodies and
horseradish peroxidase (HRP)-streptavidin (1:50) were added,
processed as per the manufacturers protocol, using azino-
bisthiosulphuric acid (ABTS) as substrate and the OD405nm
read in an ELISA Reader (Lab Systems, Helsinki, Finland).
The concentrations of cytokines were calculated against the
standard curve using standard recombinant cytokines. The
lower detection limit for this assay was 1Æ5 pg/ml for IL-10 and
7 pg/ml for IFN-c, IL-2, and IL-12. Culture supernatants from
un-stimulated cells served as the controls. Cytokines in the sera
of ALL patients and normal individuals were quantitated
similarly.
Reverse transcription polymerase chain reaction (RT-PCR)
Studies
Cellular RNA was extracted using Trizol from Achatinin-H
(0Æ10 lg)-stimulated PBMCALL. RNA (1 lg) was reverse
transcribed to cDNA using a poly (dT) oligonucleotide and
200 U Superscript II reverse transcriptase. Each PCR cycle
consisted of denaturation at 94C for 30 s, annealing at 55C
for 45 s and extension at 72C for 1 min using specific primers
for cytokines (Table I) in a Perkin-Elmer DNA thermal cycler.
The PCR products (10 ll) were analysed in agarose gel (1%)
stained with ethidium bromide and visualized under UV lamp.
A commercially prepared 100 base pair ladder was used as a
molecular weight marker. RNA isolated from unstimulated
cells served as the control. The intensity of the bands for
cytokine was determined by densitometry using the quantity
one software.
Results
Over-expression of 9-O-AcSGs on subsets of PBMCALL
In accordance with our earlier studies, the WBC count
correlated well with 9-O-AcSG expression (Pal et al, 2004a)
and the disease-specific expression of 9-O-AcSGs on PBMCALL
from B- and T-ALL patients were irrespective of their lineages
(Sinha et al, 1999a; Mandal et al, 2000; Pal et al, 2004a,b). The
distribution of 9-O-AcSGs on different haematopoetic cells
present in the population of PBMCALL showed that, although
89–95% cells were CD-19+-9-O-AcSG+, typically in a B-ALL
patient, low numbers of other cells (T, myeloid and monocyte
cells) were also present. Interestingly, even these low number
of cells (CD-7+; 2–3%, CD-13+; 3–6% and CD-14+; 8–10%)
co-expressed 9-O-AcSGs (Fig 1A). Similarly, in T-ALL patients
expressing (CD-7+-9-O-AcSG+; 93–97%) a small number of
other cells present also co-expressed 9-O-AcSGs. PBMC
subsets from normal individuals however reflected low level
(3–9%) 9-O-AcSG expression (Fig 1B).
The shift in the mean fluorescence intensity (83 to 5%) of
untreated and esterase-treated cells confirmed the O-acetylated
status of these disease-specific molecules (data not shown).
Lack of expression of 9-O-AcSGs on PBMC from AML (0Æ05–
0Æ8%) and CLL (0Æ2–0Æ7%) patients (data not shown) further
confirmed the restricted over-expression of 9-O-AcSGs only
on PBMCALL.
Achatinin-H induces proliferation of PBMCALL
To observe the stimulatory effect of Achatinin-H on PBMCALL,
cells were cultured in the absence or presence of Achatinin-H
at different doses for 48 h. While high concentration of
Achatinin-H (10–12 lg) induced cell death after 48 h, the
lower doses (0Æ01, 0Æ05 lg) could not induce any significant
lymphoproliferative response (Fig 2A). Maximal lymphopro-
liferative response by Achatinin-H (0Æ1 lg) was observed at
IFN-c Production due to Stimulation of 9-O-AcSGs in ALL
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48 h. At this dose and time, a two- to threefold lymphopro-
liferative response was observed in PBMCALL from both B and
T lineages as compared with that of unstimulated cells as
detected by the MTT assay (Fig 2B), O.D.570nm being
1Æ34 ± 0Æ25, 1Æ5 ± 0Æ28 for B and T ALL, respectively, as
compared with 0Æ522 ± 0Æ09 (Fig 2B).
Table I. Primers for cytokines.
Gene Forward Reverse Size (bp)
IFN-c 5¢TCTGCATCGTTTTGGGTTCT 3¢ 5¢CAGCTTTTCGAAGTCATCTC 3¢ 300
IL-10 5¢AGATCTCCGAGATGCCTTTCA3¢ 5¢TTTCGTATCTTCATTGTCATGTA3¢ 408
IL-2 5¢ATGTACAGGATGCAACTCCTGTCTT 3¢ 5¢GTCAGTGTTGAGATGATGCTTGAC 3¢ 458
IL-12(P40) 5¢CCAAGAACTTGCAGCAGCTGAAG3¢ 5¢ TGGGTCTATTCCGTTGTGTC 3¢ 360
GAPDH 5¢ATGGGGAAGGTGAAGGTCGG 3¢ 5¢ GGGTGCTAAGCAGTTGGT3¢ 540
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Fig 1. Overexpression of 9-O-AcSGs on subsets
of PBMCALL. (A) A representative profile of
disease-specific expression of 9-O-AcSGs on
different PBMC of a B-ALL patient, demon-
strated by staining cells with FITC-Achatinin-H
and PE-conjugated anti-CD-19, anti-CD-7, anti-
CD-13 and anti-CD-14 monoclonal antibodies
individually. Appropriate isotype matched con-
trols were used as described in Materials and
methods. (B) A representative profile of whole
blood from a normal individual, processed
similarly.
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Fig 2. Achatinin-H specifically interacts with
9-O-AcSGs on PBMCALL. (A) Dose response of
Achatinin-H on viability. A representative pro-
file of PBMCALL from a B- and T-ALL patient
were cultured in presence (B- and T-d)
or absence (B- and T-s); of Achatinin-H
(0–12 lg) for 48 h and the viability of cells were
detected by MTT assay. The data is a represen-
tative profile of n ¼ 10 patients. (B) Prolifer-
ation of PBMC from B, T-ALL, AML, CLL
patients and normal donors. Cells (1 · 105/ml)
were cultured in the absence and presence of
Achatinin-H for 48 h and proliferation was
quantitated by the MTT assay. The data is a
representative profile of 10 independent
experiments. The points represent mean ± SEM
of triplicate determinants of one of the two
replicate experiments. Cells in absence of
Achatinin-H served as control. (C) Lympho-
proliferation needs interaction between Achati-
nin-H and 9-O-AcSGs. Cells were cultured in
absence (h) or presence of Achatinin-H before
( ) and after pre-incubation with BSM ( )
and PBMCALL ablated of O-acetylations ( ) as
described in Materials and methods.
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No lymphoproliferation was observed when PBMCALL were
cultured in presence of Achatinin-H preincubated with the
optimum inhibitory concentration of BSM (Fig 2C). PBMCALL
ablated of O-acetylations, obtained by treating cells with O-
acetyl esterase, cultured in presence of Achatinin-H, did not
show any proliferation (Fig 2C). BSM alone, in the absence of
Achatinin-H, under similar condition, showed no proliferative
response. However, the addition of BSM did not induce cell
death.
PBMC from AML and CLL patients (Fig 2B) did not show
any proliferation with this dose of Achatinin-H (0Æ1 lg) under
identical conditions. PBMC from normal individuals, although
expressing a minimum level of 9-O-AcSGs showed low affinity
towards Achatinin-H (Pal et al, 2004a) and did not show any
proliferation with 0Æ1 lg of Achatinin-H.
Achatinin-H stimulation predominantly induces IFN-c
To understand the effect of stimulation of PBMCALL by
Achatinin-H (0Æ1 lg), we investigated the (i) the cytokine
release, (ii) cytokine in serum (iii) expression of these
cytokines at the genetic level.
(i) Enhanced IFN-c secretion by stimulated PBMCALL. An
enhanced release of IFN-c by cells stimulated with Achatinin-
H (0Æ1 lg) was observed even after 6 h (105 ± 5 pg/ml) of
exposure, increasing gradually at 24 h (456 ± 10 pg/ml) and at
48 h (673 ± 11 pg/ml; Fig 3A). The secretion of IL-10
followed a similar pattern, but with a significantly low
amount of release, 40 ± 15 and 70 ± 20 after 24 and 48 h of
stimulation respectively. The release of IL-2 and IL-12 were
25 ± 10 and 17 ± 6 pg/ml, respectively, under similar
conditions (Fig 3A).
(ii) Increased IFN-c level in serum of ALL patients at
presentation. In order to understand the in vivo situation, we
have monitored the level of IFN-c both in ALL patients, at
presentation, i.e. prior to therapy and normal sera. Elevated
level of IFN-c (650–950 pg/ml) was observed in the sera of
ALL patients, which was almost three- to fourfold higher than
normal serum (Fig 3B). However, the level of other cytokines
in these patients was low.
(iii) Increased mRNA expression of IFN-c. Cytokine transcripts
of IFN-c were consistently detected in PBMCALL, at the genetic
level, in response to Achatinin-H (0Æ1 lg) stimulation (Fig 4).
IFN-c transcripts were over-expressed after 48 h of stimulation
while the expression of IL-12 and IL-2 remained constant,
reflected by densitometry scanning (Fig 4). The release of
IL-10 after stimulation with Achatinin-H was much less than
that of IFN-c. Un-stimulated cells revealed synthesis of basal
level of cytokines.
Discussion
Assessment of the O-acetylated sialoglycoconjugates in ALL is a
relatively new domain in leukaemia sialobiology. Over-expres-
sion of 9-O-AcSGs (90 and 120 kDa) on PBMCALL (Sinha et al,
1999a; Pal et al, 2004a,b) and the concomitant elevated level of
anti-9-O-AcSG antibodies in sera (Pal et al, 2000, 2001, 2004c)
of ALL patients prior to therapy have been documented.
The gradual reduction in the expression of the disease-specific
9-O-AcSGs (90 and 120 kDa) with therapy established their800
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Fig 3. Release of cytokines by PBMCALL due to stimulation with
Achatinin-H. (A) PMBCALL were cultured in the presence of Achta-
tinin-H (0Æ1 lg) for 48 h. The concentration of the released cytokines
in the culture supernatant was detected by ELISA as described in
Materials and methods. Release of cytokines by the unstimulated cells
served as the control. The data is a representative profile of ALL
patients (n ¼ 30). The points represent mean ± SEM of triplicate
determinants of one of the two replicate experiments. (B) Increased
level of IFN-c in sera of ALL patients. Levels of cytokines in the sera of
B- and T-ALL patients, prior to therapy (n ¼ 10), and normal indi-
viduals (n ¼ 10) were quantitated by ELISA.
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Fig 4. Cytokine mRNA expression in Achatinin-H stimulated
PBMCALL. Total RNA from Achatinin-H-stimulated (0Æ1 lg)
PBMCALL was isolated and the expression of cytokines at different time
points (0–48 h) was analysed by RT-PCR as described in Materials and
methods. GAPDH served as the housekeeping gene. The mRNA
expression of unstimulated cell served as the control. The values were
compared by densitometric score and this is represented in the fold of
increase in band intensity as compared with the expression of GAPDH
at the respective time points. The data is a representative profile of 10
ALL patients.
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diagnostic and prognostic potential (Pal et al, 2004a). Previous
studies have conclusively established the expression of high
affinity 120 and 90 kDa 9-O-AcSGs on leukaemic lymphoblasts
(Pal et al, 2004a). These high affinity 9-O-AcSGs were found to
be highly active as they can be stimulated even with a very low
dose of Achatinin-H (Sinha et al, 1999b–d). The observation
suggests that 9-O-AcSGs possibly play a key role in regulating
signalling for proliferation.
The major achievement of this finding has been the (i)
expression of 9-O-AcSGs on different haematopoetic cells in
ALL, irrespective of lineage (ii) stimulation of such disease-
specific 9-O-AcSGs, leading to enhanced production of IFN-c
demonstrating the biological consequence to lymphoprolifer-
ation.
Our results are suggestive of a major defect in the
glycosylation pattern on the haematopoetic cells of these
children, as demonstrated by the overexpression of 9-O-AcSGs
not only on T- and B-lymphocytes, but also on monocytes,
and myeloid cells of these patients (Fig 1A). The key role in
generating such aberrant glycosylations may be attributed to a
group of enzymes, namely O-acetyltransferase, sialyltransferas-
es, sialidase and O-acetylesterases regulating the metabolism of
sialoglycoconjugates (Shen et al, 2004). Currently, no molecu-
lar information is available about these enzymes and studies
are underway to detect their altered expression in ALL.
The elevated levels of 9-O-AcSG on all cells in the peripheral
blood suggest that this may well be a general response to the
proliferation of acute leukaemic cells. This has clearly been
demonstrated by activating the newly-induced 9-O-AcSAa2-
6GalNAc glycotopes on PBMCALL with Achatinin-H (Fig 2A-
C). This specific interaction led to a significant lymphopro-
liferative response, as reflected by the variations in stimulation
index with different dose of Achatinin-H (Fig 2B), suggesting
the functionally active nature of the disease-specific 9-O-
AcSGs. Absence of lymphoproliferation of PBMCALL by
Achatinin-H was observed when 9-O-AcSA present on
PBMCALL was blocked by preincubation with BSM, or O-
acetylation ablated PBMCALL were used for stimulation,
reconfirming the involvement of O-acetyl group in this
stimulation (Fig 2C). In contrast, the lack of proliferation of
PBMC of AML and CLL patients under similar conditions
suggested disease-specific stimulation via interaction with 9-O-
AcSGs (Fig 2B). PBMCN could not be stimulated with this
dose of lectin, corroborating our earlier observation (Sinha
et al, 1999b–d) and further confirming the disease-specific
interaction (Fig 2B).
In vitro interaction of 9-O-AcSGs on PBMCALL with
Achatinin-H led to the release of a high amount of IFN-c
(Fig 3A) in the culture supernatant together with an increased
mRNA level (Fig 4) indicating the potential of 9-O-AcSGs in
mediating the signalling responses. Normal B cells have been
reported to be incapable of IFN-c production (Young, 1997).
Since the study population included patients with around 80–
90% lymphoblasts in the peripheral blood it may be envisaged
that the release of IFN-c was solely mediated by leukaemic
lymphoblasts. However, as a small population of other cells
also expressed 9-O-AcSGs, their collective interplay cannot be
ruled out. The exact pathway of the downstream events leading
to IFN-c production in ALL is yet to be investigated.
Cytokines are released in response to a diverse range of
cellular stresses that profoundly affect several stages of cancer
formation, growth of tumours in vivo, progression and playing
a significant role in immunosurveillance against malignant
cells (Colombo & Trinchieri, 2002). Abundant interactions
have been reported to transform the complex cytokine network
regulation of normal haematopoiesis into an even more
interlaced patchwork controlling leukaemic haematopoiesis
(Dranoff, 2004). IFN-c is reported to influence many biolo-
gical processes along with the production of NO2
) and iNOS
in certain tumours (Tachibana et al, 2000; Alexandrova et al,
2001) and a link between IFN-c-induced iNOS expression and
inhibition of spontaneous apoptosis in B-CLL has been
reported (Levesque et al, 2003). The contributory role of
other molecules in aiding lymphoblast survival remains to be
investigated in greater details.
In addition, the observed three- to fourfold increase in the
serum concentration of IFN-c as compared with normal
individuals (Fig 3B) is probably indicative of the presence of
ligands for 9-O-AcSAa2-6GalNAc glycotope in the patients’
serum, regulating the functional level of IFN-c in ALL. The
presence of anti-9-O-AcSGs in the sera of these children (Pal
et al, 2000, 2001, 2004c) may acts as ligand for newly-induced
9-O-AcSGs on PBMCALL. Thus, it may be hypothesized that
the presence of anti-9-O-AcSG antibody in the milieu of other
molecules in patients’ serum can mediate the observed effects.
However, the exact contributory molecules to the pathway are
yet to be elucidated and studies are currently ongoing to
address this hypothesis.
In summary, we have established that the disease-specific
9-O-AcSGs are abundantly overexpressed on different haema-
topoietic cells in ALL. These O-acetylated sialoglycoproteins
are functionally active molecules, which, when stimulated with
a ligand specific for its glycotope, is capable of mediating
downstream effects revealed by lymphoproliferative responses
with elevated levels of IFN-c.
Thus, this observation is suggestive of a possible role of
over-expressed disease-specific 9-O-AcSGs in regulating signal-
ling for proliferation. Controlled expression of these molecules
may be exploited for therapeutic applications, promising
beneficial effects to children with ALL.
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